Read more about the article Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients
Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients

Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients

Lonvo-z showed a 98% reduction in HAE attacks for 10 patients over three-year follow-up, demonstrating promising safety and efficacy.Quiver AI SummaryIntellia Therapeutics has announced promising three-year follow-up data from its…

Continue ReadingIntellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients
Read more about the article Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug

Upstream Bio presents data suggesting verekitug offers greater potency than tezepelumab in targeting inflammatory diseases.Quiver AI SummaryUpstream Bio, Inc. presented data at the European Academy of Allergy & Clinical Immunology…

Continue ReadingUpstream Bio Presents Pharmacology Modeling Data Supporting Verekitug

End of content

No more pages to load